

This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

BUSY WEEK? Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director **Patricia Van Arnum**.

Sponsored By:

 <p>spectrum CHEMICAL MFG CORP 800.772.8786 SpectrumChemical.com</p>	<p>Spectrum Offers 1200+ USP/NF cGMP Products. Order Your 2016 USP Catalog!</p> <p>Click Here</p>	
--	---	---

1. [AstraZeneca Acquires Majority Stake in Acerta Pharma](#)

AstraZeneca has completed its previously announced acquisition of a majority equity stake in Acerta Pharma, a privately owned biopharmaceutical company based in the Netherlands and US, in a deal valued up to \$4 billion. The deal provides AstraZeneca with a cancer therapy, an oral Bruton's tyrosine kinase inhibitor, acalabrutinib. [Read More](#)

2. [Takeda, Mersana Partner Again in \\$830 Million Oncology Deal](#)

Mersana Therapeutics and Takeda Pharmaceutical have formed a new strategic partnership granting Takeda rights to Mersana's lead product candidate, XMT-1522, an antibody drug conjugate, outside the United States and Canada in a deal valued up to \$830 million. [Read More](#)

3. [Sun Pharma Launches Generic Version of Novartis' Gleevec](#)

Sun Pharma has launched imatinib mesylate tablets, a generic version of Novartis' anticancer therapy, Gleevec, Novartis' top-selling oncology drug in 2015 with sales of \$4.66 billion. [Read More](#)

4. [FDA Launches Plan for Opioid Medicines](#)

In response to the opioid abuse epidemic, Dr. Robert Califf, the US Food and Drug Administration's Deputy Commissioner for Medical Products and Tobacco, along with other FDA leaders, called for an action plan to reassess the agency's approach to opioid medications. The plan includes additional measures for approving new drug applications for an opioid that does not have abuse-deterrent properties. [Read More](#)

5. [Valeant's Bausch and Lomb Issues Voluntary Recall of More than 1 Million Bottles of Eye-Care Solution](#)

Bausch and Lomb, part of Valeant Pharmaceuticals, has issued a Class III voluntary recall of more than 1 million bottles of tropicamide ophthalmic solution due to a labeling and packaging error: the package insert is missing updates compared with the reference drug insert. [Read More](#)

6. [Lonza To Launch Parenteral Drug Product Services](#)

Lonza plans to expand its pharmaceutical and biotechnology segment by offering development and manufacturing services for clinical outsourcing of drug products for parenteral dosage forms. The new services, scheduled for launch in the fourth quarter of 2016, will be headed by Prof. Dr. Hanns-Christian Mahler, who for 10 years led the departments of Pharmaceutical Development & Supplies

and Formulation R&D Biologics for Roche. [Read More](#)

7. [GSK, Adaptimmune Expand Immuno-Oncology Pact](#)

GlaxoSmithKline and Adaptimmune Therapeutics, a biopharmaceutical company focused on the use of T-cell receptor (TCR) engineered T-cell therapy to treat cancer, have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune's lead clinical cancer program in a deal valued up to \$500 million. [Read More](#)

8. [Teva, AbCellera Sign Pact for Rare mAbs](#)

In an effort to boost its proprietary drug platform, Teva Pharmaceutical Industries has formed a research pact with AbCellera for the discovery of rare monoclonal antibodies. [Read More](#)

9. [Eli Lilly, Roche Partner for Alzheimer's Diagnostic](#)

Eli Lilly and Company has partnered with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42, an important marker for Alzheimer's disease. [Read More](#)

10. [Sanofi Launches R&D to Combat Zika Virus](#)

Sanofi Pasteur, the vaccines division of Sanofi, has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease. The company hopes to leverage its expertise with vaccines for viruses in the same family as the Zika virus. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

[Forward this email](#)



This email was sent to esanders@dcat.org by dcatnews@dcat.org | [Update Profile/Email Address](#) | Rapid removal with [SafeUnsubscribe](#)™ | [About our service provider](#).

Drug, Chemical, & Associated Technologies Association | One Union Street | Suite 208 | Robbinsville | NJ | 08691